|
Methodological aspects of recent major guidelines for hypertension |
||||||
| Guideline |
Development group describeda |
New systematic reviewing |
Used existing systematic reviewsc |
Literature searchb |
Grading of evidenced |
Grading of recommendationsd |
|
|
||||||
| CMA |
P |
N |
Y |
Y |
Y |
Y |
| WHO |
P |
N |
Y |
N |
N |
N |
| VHA |
P |
N |
N |
Y |
Y |
Y |
| SIGN |
Y |
N |
Y |
Y |
Y |
Y |
| ESH |
Y |
N |
Y |
N |
N |
N |
| ICSI |
N |
N |
y |
N |
Y |
N |
| JNC |
P |
N |
Y |
N |
Y |
N |
| SA |
P |
N |
y |
N |
N |
N |
| BHS |
P |
N |
Y |
N |
Y |
Y |
| NICE |
Y |
Y |
Y |
Y |
Y |
Y |
|
a Y/N: Includes/does not include description of stakeholders involved in the development process, including patient representatives and any conflicts of interest. P: Partially – a list of names with institutional affiliations was provided. b Y/N: Searches were/were not undertaken, at least through Medline. c Y: Made extensive use of existing systematic reviews (referenced 7 or more). y: Made partial use of existing systematic reviews (referenced 6 or less). N: Did not use existing systematic reviews. d Y/N: Reports/does not report explicit grading of the quality of the supporting evidence/recommendations. | ||||||
Campbell et al. BMC Health Services Research 2006 6:47 doi:10.1186/1472-6963-6-47 |
||||||